Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group

Blood

Volumn 103, Issue 4, 2004, Pages 1237-1243

  Sanz, Miguel A ^a   Martín, Guillermo ^b   González, Marcos ^b   León, Angel ^b   Rayón, Chelo ^b   Rivàs, Concha ^b   Colomer, Dolors ^b   Amutio, Elena ^b   Capote, Francisco J ^b   Milone, Gustavo A ^b   De La Serna, Javier ^b   Román, José ^b   Barragán, Eva ^b   Bergua, Juan ^b   Escoda, Lourdes ^b   Parody, Ricardo ^b   Negri, Silvia ^b   Calasanz, María J ^b   Bolufer, Pascual ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL TRIAL; CONSOLIDATION THERAPY; CYTOPENIA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK; RETINOIC ACID SYNDROME; RISK ADAPTED TREATMENT;

EID: 10744220024     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2462     Document Type: Article

References (23)

1. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukaemia: evolving strategies. Blood. 2002;99:759-767.
2. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
3. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukemia Working Party: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
4. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
5. Fenaux P, Chastang C, Sanz MA, et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
6. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014-1021.
7. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;16:78-85.
8. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia. 2000;14:1362-1370.
9. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
10. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. Br J Haematol. 1976;33:451-461.
11. Bennett JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Ann Intern Med. 1980;92:280-288.
12. Bolufer P, Barragán E, Sanz MA, et al. Preliminary experience in external quality control of RT-PCR PM/RARα detection in promyelocytic leukemia. Leukemia. 1998;12:2024-2028.
13. Bolufer P, Lo Coco F, Grimwade D, et al. Variability in the levels of PML-RARα fusion transcripts detected by laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica. 2001;86:570-576.
14. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
15. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med. 1994;120:278-286.
16. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
18. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
19. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med. 1993;12:737-751.
20. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
21. Avvisati G, ten Cate JW, Büller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2:122-124.
22. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
23. Sanz MA, Martín G, Barragán E, et al. All-trans retinoic acid and anthracycline reinforcement in consolidation improve the outcome of patients with intermediate and high-risk acute promyelocytic leukemia: results of the Spanish PETHEMA trial LPA99 [abstract]. Blood. 2002;98:155a.